Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi Is Injecting Almost Half A Billion Dollars Each Year Into mRNA Tech Driving Pfizer, Moderna Covid Shots
07:07am, Tuesday, 29'th Jun 2021
The vaccine heavyweight will invest nearly $480 million a year to develop mRNA vaccines for other diseases.
Sanofi Divests 16 Consumer Health Brands To Stada
02:16pm, Monday, 28'th Jun 2021
Amid a reorganization scheme aimed at slashing costs and prioritizing blockbuster immunology Dupixent, Sanofi SA (NASDAQ: SNY) will offload 16 consumer health products to Germany's Stada Arzneimi
Sanofi's Soliqua Shows Improved Blood Sugar Control Without Weigh Gain Against Premixed Insulin
12:40pm, Monday, 28'th Jun 2021
Sanofi SA (NASDAQ: SNY) has announced new study data of Soliqua 100/33 (insulin glargine and lixisenatide injection) that met its two primary endpoints and all key secondary endpoints in a head-to-
Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings
08:51am, Friday, 25'th Jun 2021
The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two additional indications - basal cell carcinoma (BCC
Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine
12:02pm, Wednesday, 23'rd Jun 2021
Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.
Sanofi SA (SNY) at Guggenheim Biopharma Strategy Series Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation Conference (Transcript)
Sanofi, Translate Bio Initiate Early-Stage mRNA Influenza Vaccine Trial
06:32am, Tuesday, 22'nd Jun 2021
Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal infl
Sanofi's (SNY) Aubagio Gets EU Nod for MS in Pediatric Patients
01:32pm, Monday, 21'st Jun 2021
The European Commission approves Sanofi's (SNY) Aubagio for the treatment of pediatric patients aged 10 to 17 years with relapsing-remitting multiple sclerosis.
How This Pharma Company Can Benefit From Its Competitors
05:11am, Sunday, 20'th Jun 2021
Delays in FDA approval for Incyte could spell good news for Sanofi.
Europe Approves Sanofi's Expanded Use Of Aubagio In Pediatric Patients With Multiple Sclerosis
03:27pm, Friday, 18'th Jun 2021
The European Commission has approved Sanofi SA's (NASDAQ: SNY) Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRM
Sanofi Scores FDA Approval For Flu-Shot Facility In US
02:00pm, Thursday, 17'th Jun 2021
The FDA has approved Sanofi SA's (NASDAQ: SNY) newly completed plant in Swiftwater, Pennsylvania. The license will allow Sanofi to begin production of its Fluzone High-Dose vaccine for the 2021-22
RAPT Reports Positive Data From Atopic Dermatitis Study
12:47pm, Wednesday, 16'th Jun 2021
RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.
Sanofi's Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA Rejection
02:31pm, Friday, 11'th Jun 2021
Sanofi SA's (NASDAQ: SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold agglutinin disease. This rare disorder can cause severe anemia wit
Sanofi SA (SNY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)
07:15pm, Wednesday, 09'th Jun 2021
Sanofi SA (SNY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)
Drug Startups Eye Quicker Profits Under China's New Fast-Track Approvals
02:01pm, Wednesday, 09'th Jun 2021
A recent regulatory overhaul designed to speed up development and approval of new drugs in China has been welcomed by global pharma giants and local startups alike, aimed at bringing their latest cutt
